JERUSALEM, Israel, April 3 /PRNewswire-FirstCall/ -- IDenta Corp. today announced that a co-venture marketing agreement has been signed with APH Group based in Savannah, Georgia. The agreement was reached after IDenta executives reviewed numerous proposals to open new U.S. retail and civilian sales channels for IDenta’s proprietary drug detection kits.
“It was an easy choice deciding to team with APH,” reported Yaacov Shoham, IDenta President and CEO. “While other companies offered some of the marketing elements IDenta specified, APH presented the most comprehensive turn-key solution.” IDenta believes there is significant interest and need for its products in school systems, with employers of all sizes, in family settings and in numerous other vertical markets in need of verifiable drug detection.
Shoham and IDenta representatives met with APH executives, CEO Susan Brod and President Tony Higgins, during his recent U.S. trade mission. “The long-term objective of this initiative is to eventually integrate IDenta’s product line with nationwide sales forces directed by APH Group,” explained Higgins. The sales strategy and roll-out process are now being formally developed. Results from the program are expected to begin being tallied in the latter part of 2006.
The civilian and professional market for drug detection products is estimated to be over $100 million dollars.
About APH Group
The APH Group, founded in 1995, provides market expansion and business incubator services to avant-garde, international companies who have outstanding products, and are positioned and prepared for rapid market expansion. APH offers customized sales outsourcing services designed to meet the specific needs of each client, and has offices in Savannah, New York, London and Israel. www.aphgroup.com
About IDenta
IDenta Corporation is a leading developer of proprietary on-site drug detection kits used by governments and security forces around the world. Information concerning IDenta’s business plan and product line, including rapid test kits (substance only) for the detection of marijuana, hashish, ecstasy, cocaine, crack, heroin and methamphetamines may be found at www.IDenta.biz and www.drugsdetector.com
IDenta proudly supports “D.A.M.M.A.D.D.,” Dads and Mad Moms Against Drug Dealers, (www.dammadd.org)
For Investor Relations, lobbying interests or information concerning IDenta’s products internationally contact:
Yaacov Shoham, IDenta Corp., CEO Tel: +972-52-6554487, +972-8-9716874 Fax: +972-8-9716875 fpi@drugsdetector.com For Investor Relations in the United States contact: Randy Jacobs, SITCOM LLC +1-800-316-9437 rjacobs@mvest.us
Certain of the statements contained herein may be, within the meaning of the federal securities laws, “forward-looking statements” that are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements are based on management’s expectations as of the date hereof, and the company does not undertake any responsibility to update any of these statements in the future.
IDenta Corp.
CONTACT: Yaacov Shoham, IDenta Corp., CEO, Tel: +972-52-6554487,+972-8-9716874, Fax: +972-8-9716875, fpi@drugsdetector.com, For InvestorRelations in the United States contact: Randy Jacobs, SITCOM LLC,+1-800-316-9437, rjacobs@mvest.us
